Full text
PDFPage 494
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Brambilla C., Rossi A., Bonfante V., Ferrari L., Villani F., Crippa F., Bonadonna G. Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat Rep. 1986 Feb;70(2):261–266. [PubMed] [Google Scholar]
- Henderson I. C. Adjuvant therapy for breast cancer. N Engl J Med. 1988 Feb 18;318(7):443–444. doi: 10.1056/NEJM198802183180709. [DOI] [PubMed] [Google Scholar]
- Jain K. K., Casper E. S., Geller N. L., Hakes T. B., Kaufman R. J., Currie V., Schwartz W., Cassidy C., Petroni G. R., Young C. W. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol. 1985 Jun;3(6):818–826. doi: 10.1200/JCO.1985.3.6.818. [DOI] [PubMed] [Google Scholar]
- Levine M. N., Gent M., Hirsh J., Arnold A., Goodyear M. D., Hryniuk W., De Pauw S. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med. 1988 Feb 18;318(7):404–407. doi: 10.1056/NEJM198802183180703. [DOI] [PubMed] [Google Scholar]
- Powles T. J., Coombes R. C., Smith I. E., Jones J. M., Ford H. T., Gazet J. C. Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet. 1980 Mar 15;1(8168 Pt 1):580–582. doi: 10.1016/s0140-6736(80)91066-1. [DOI] [PubMed] [Google Scholar]